AI Consensus Investment Thesis
VEEV: Veeva Systems Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Veeva Systems: 1-Year and 5-Year Forecast Outlook and Rating
Veeva Systems (VEEV) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $286 for , with -10.25% expected return (-10.25% including net dividends) and a SELL ALL rating.
The 5-year target is $426 for , with +33.68% expected return (+33.68% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 319, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Veeva Systems Flagship Insight
Life Sciences Cloud Decoupling Sparks Strategic Margin Expansion Across Global Biopharma
High consensus confirms that mission-critical regulatory compliance moats and third-party royalty eliminations drive structural cash flow compounding. Sharp divergence centers on whether forty-two times trailing earnings and migration-induced competitive bidding will compress valuation multiples under persistent five-percent sovereign bond yields.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Warren Buffett (Value Purist)
Universal Investor (Polymath)
Superintelligence (Anthropologist)
Sherlock Holmes (Whistleblower)
Machiavelli (Insider)
J.P. Morgan (Titan)
Michael Burry (Vulture)
Elon Musk (Visionary)
Ray Dalio (Strategist)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Veeva Systems: forecast questions
What is Veeva Systems (VEEV)'s 1-year price forecast?
Veeva Systems's 1-year target is $286 for Sept 2027. The current AI rating is SELL ALL. The expected return from the recorded close is -10.25%, or -10.25% modeled return including net dividends. Latest available market price: USD 319, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Veeva Systems (VEEV)'s 5-year price forecast?
Veeva Systems's 5-year target is $426 for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +33.68%, or +33.68% modeled return including net dividends. Latest available market price: USD 319, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 319, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Veeva Systems forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Veeva Systems differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Veeva Systems is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Veeva Systems: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Veeva Systems at the latest market close (20 Oct 2026): $13,368 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
The central investment thesis evaluates the interplay between an entrenched vertical software monopoly and valuation duration risk under restrictive monetary policy. The foundational economic engine is insulated by stringent GxP and 21 CFR Part 11 regulatory compliance mandates, making wholesale displacement of clinical and safety systems economically irrational. The planned operational decoupling from legacy third-party platform infrastructure represents a structural margin unlock, eliminating tens of millions in annual hosting royalties and lifting normalized gross margins toward 78%. However, trading at forty-two times trailing earnings against elevated sovereign bond yields leaves no margin for implementation missteps, as higher capital hurdle rates exert persistent multiple compression.
Key insights
- Compulsory platform migrations temporarily reopen procurement cycles, enabling competing cloud alliances to contest front-office commercial accounts while clinical suites remain unassailable.
- Professional services gross margin dilution during peak customer onboarding conceals underlying subscription operating leverage until implementation bulges subside.
- Pristine zero-debt balance sheets generate accretive interest income, funding programmatic buybacks that absorb equity compensation and amplify per-share compounding.
Veeva Systems: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 319, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 260. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $263 | +0.89% | -17.47% | -17.47% | Third-quarter subscription billings demonstrate resilient core demand, but elevated discount rates and valuation scrutiny in enterprise software keep price gains modest as investors await validation of early proprietary migration milestones. | $250 | $271 | $750 | |
| $271 | +3.13% | -14.96% | -14.96% | Fiscal 2027 full-year earnings confirm solid double-digit recurring revenue expansion and strong cash conversion. Expanding enterprise share repurchases provide immediate downside support against persistent sovereign yield volatility. | $252 | $284 | $736 | |
| $279 | +3.13% | -12.45% | -12.45% | First-quarter fiscal 2028 disclosures reveal steady migration commitments among tier-one biopharmas. High Development Cloud retention offsets migration-related professional services cost dilution, supporting steady equity accumulation. | $258 | $293 | $743 | |
| $286 | +2.42% | -10.25% | -10.25% | Seasonal summer procurement pauses and elevated risk-free yields induce selective valuation consolidation. Operational cash generation and unencumbered balance sheet liquidity preserve price stability across volatile software markets. | $260 | $304 | $755 | |
| $294 | +2.77% | -7.74% | -7.74% | Year-end compliance budget commitments drive healthy module cross-selling across Clinical and Quality suites. Initial revenue from specialized agentic automation pilots provides constructive fundamental momentum into year-end. | $265 | $314 | $776 | |
| $302 | +2.91% | -5.23% | -5.23% | Fiscal 2028 reporting validates non-GAAP operating margin resilience above forty-four percent. Active equity retirements cushion per-share intrinsic value even as elevated borrowing benchmarks cap broader market multiple expansion. | $260 | $329 | $787 | |
| $309 | +2.04% | -3.03% | -3.03% | Initial gross margin benefits emerge as the first major cohort of customer migrations eliminates external platform royalty obligations. Sustained cash flow generation prompts positive institutional earnings revisions. | $268 | $342 | $803 | |
| $317 | +2.66% | -0.52% | -0.52% | Mid-year competitive discounting from rival front-office software providers prolongs renewal negotiations in mid-tier accounts. However, non-discretionary regulatory data lock-in prevents material client defection, maintaining modest price gains. | $273 | $353 | $812 | |
| $326 | +3.00% | +2.30% | +2.30% | Expanding enterprise adoption of unified clinical trial data management accelerates subscription backlog. Pristine operating cash flows and consistent share repurchases absorb modest tech sector multiple compression. | $281 | $367 | $839 | |
| $337 | +3.16% | +5.75% | +5.75% | Fiscal 2029 results highlight operating cash flows crossing two billion dollars. Royalty reductions begin flowing directly into bottom-line profits, proving the fundamental durability of sovereign software delivery. | $284 | $385 | $851 | |
| $346 | +2.74% | +8.58% | +8.58% | Enterprise cross-selling expands into adjacent medical device and diagnostic accounts. Steady subscription growth counterbalances customer migration support expenses, supporting consistent quarterly capital appreciation. | $292 | $397 | $872 | |
| $354 | +2.43% | +11.09% | +11.09% | Approaching the scheduled legacy platform support retirement creates implementation congestion for late-migrating accounts. Services margins experience transient friction, but high subscription visibility prevents valuation drawdowns. | $287 | $412 | $886 | |
| $359 | +1.37% | +12.66% | +12.66% | The formal conclusion of legacy platform support passes with negligible customer churn. Decoupling from third-party hosting infrastructure permanently resolves multi-year platform uncertainty, restoring strong institutional investor sentiment. | $292 | $425 | $910 | |
| $371 | +3.28% | +16.42% | +16.42% | Fiscal 2030 financial disclosures showcase structural gross margin expansion toward seventy-eight percent. Eliminating external licensing royalties fuels an earnings beat, driving healthy fundamental share price appreciation. | $304 | $446 | $916 | |
| $381 | +2.73% | +19.56% | +19.56% | First-quarter post-migration operations demonstrate pristine operating leverage. Commercial teams redirect focus from replatforming defenses to adjacent data and safety cross-selling, sustaining double-digit earnings compounding. | $307 | $464 | $937 | |
| $390 | +2.34% | +22.38% | +22.38% | Autonomous agentic workflows within clinical documentation achieve broader commercial monetization. Substantial balance sheet cash reserves and ongoing buybacks provide a dependable fundamental floor against macro rotation. | $304 | $478 | $947 | |
| $398 | +2.12% | +24.89% | +24.89% | Year-end enterprise renewals confirm mature market leadership across global life sciences. Consistent cash conversion and shrinking share float support dependable equity compounding as top-line growth normalizes. | $310 | $497 | $970 | |
| $408 | +2.50% | +28.03% | +28.03% | Fiscal 2031 reporting establishes record free cash flow generation exceeding 2.4 billion dollars. While mature scale tempers percentage revenue growth, robust capital returns sustain steady shareholder value creation. | $316 | $517 | $980 | |
| $417 | +2.21% | +30.86% | +30.86% | Expanding international clinical trial activity and deep regulatory entrenchment maintain predictable recurring revenues. High software margins and debt-free operations reward patient long-term institutional capital. | $313 | $532 | $1,000 | |
| $426 | +2.16% | +33.68% | +33.68% | The five-year scenario concludes with the enterprise established as a sovereign vertical software utility. Terminal free cash flow conversion and disciplined share retirements deliver resilient risk-adjusted compounded returns. | $316 | $548 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Veeva Systems Stock Analysis & Scenarios Deep Dive
Veeva Systems: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market sentiment views the business as an untouchable life sciences software monopoly that has successfully de-risked its platform divorce. Consensus expects effortless mid-teens subscription compounding and smooth AI monetization, treating historical ninety-nine percent retention as guaranteed. The crowd assumes a rich forty-two times trailing multiple remains permanently justified by elite forty-percent free cash flow margins, largely discounting discount-rate gravity.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The reports establish no compelling directional gap; the crowd overestimates valuation resilience while underestimating structural post-migration cash flow durability. The market incorrectly views the platform separation as a mere defensive chore rather than a permanent gross margin harvest that recaptures millions in third-party royalties. However, the crowd ignores that re-implementation reopens settled enterprise accounts to aggressive competitive bidding. At forty-two times earnings, fundamental quality is already fully priced.
Repricing Catalyst
What could make the market recognize and close that gap? Consecutive earnings reports through fiscal 2028 will serve as the primary catalyst, proving whether gross margins expand past 77% as peak migration consulting costs subside. Observable evidence that top-twenty pharmaceutical clients completed cutovers without commercial defection will definitively settle the competitive narrative. Upward revisions to recurring subscription guidance—rather than temporary implementation services spikes—will trigger institutional repricing.
Veeva Systems: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Greed
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Growing Awareness
Analysts agree that operational execution is pristine and regulatory moats are intact. The decisive tension centers on whether forty-two times trailing earnings leaves room for multiple contraction under five-percent Treasury yields, dictating whether five-year returns match earnings compounding or lag significantly.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regime of restrictive central bank benchmark rates and five-percent Treasury yields is a valuation headwind yet an operational tailwind. Elevated discount rates compress long-duration software multiples. Conversely, life sciences compliance spending is non-discretionary, and holding zero debt alongside substantial liquid reserves generates accretive interest income while insulating cash flows from tightening corporate credit spreads.
Advisor Disagreement
What do our AI Advisors disagree about most? The fundamental debate across reports centers on whether the mandatory platform migration represents an offensive margin catalyst or a vulnerable window of competitive contestability. Bullish views argue that twelve top-twenty pharmaceutical commitments prove insurmountable switching moats, ensuring that royalty eliminations flow directly into structural gross margin expansion toward 78%. Skeptics counter that forced re-implementation is the only moment in a decade when enterprise clients can credibly tender competitive bids, while elevated real interest rates guarantee multiple compression from forty-two times earnings. Monitoring gross margins and renewal win rates across the top twenty drugmakers will resolve whether platform sovereignty or procurement friction prevails.
Veeva Systems: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Proprietary platform royalty elimination harvest | Operational Efficiency | +22% | +28% | Transitioning commercial life sciences customers from third-party hosting to proprietary cloud architecture permanently extinguishes tens of millions in annual platform royalties. This decoupling expands gross margins toward 78% and lifts operating cash flow conversion. The structural cost reset provides permanent operational leverage as biopharma clients standardize on unified data infrastructure. |
| Regulatory validation lock-in dominance | Competitive Positioning | +20% | +24% | Stringent global health authority mandates, including FDA 21 CFR Part 11 and GxP compliance rules, impose punitive costs on software switching. Clinical trial data management, electronic master files, and pharmacovigilance workflows form an irreplaceable system of record, preserving gross customer retention above 98% and ensuring highly predictable multi-year subscription revenues. |
| Domain-specific agentic workflow monetization | Innovation And Product | +15% | +18% | Integrating deterministic, audit-ready artificial intelligence agents directly into validated clinical documentation, safety intake, and regulatory filings unlocks premium software tiers. Because regulated life sciences data cannot touch unvalidated public models, specialized domain agents capture enterprise automation budgets, expanding contract values and lifetime customer revenue without requiring physical server infrastructure. |
| Unlevered cash-flow-funded share retirement | Capital Allocation | +11% | +10% | Generating over 1.6 billion dollars in annual free cash flow with capital expenditures below 1% of revenue establishes formidable capital return firepower. Management systematically deploys surplus liquidity into multi-billion-dollar share repurchases, neutralizing stock compensation dilution, shrinking diluted share count, and mechanically compounding per-share intrinsic value throughout the forecast horizon. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Elevated discount-rate multiple compression | Macroeconomic And Macrofinancial | -16% | -3.0% | Trading near forty-two times trailing earnings in an economic regime defined by five-percent benchmark Treasury yields leaves equities highly vulnerable to multiple compression. Higher corporate hurdle rates reduce the present value of distant cash flows, ensuring that terminal multiple contraction from 42x toward 28x significantly offsets fundamental operational earnings growth. |
| Commercial cloud competitive alliance counteroffensive | Competitive Positioning | -12% | -11% | Rival enterprise cloud and healthcare data alliances are aggressively targeting commercial pharmaceutical renewals during the mandatory platform replatforming window. Forced migration temporarily collapses customer inertia, prompting enterprise procurement teams to seek bundled discounting. This competitive dynamic lengthens enterprise sales cycles and caps near-term pricing power on commercial renewals. |
| Professional services migration margin dilution | Operational Efficiency | -9.0% | -10% | Replatforming hundreds of complex global pharmaceutical enterprise deployments requires extensive deployment consulting and customized data validation. Because professional services carry structural gross margins near 30% compared to 85% for subscriptions, this ongoing services revenue surge temporarily dilutes blended corporate gross margins and ties up technical engineering personnel. |
| Biopharma pipeline procurement rationalization | Sector And Industry | -8.0% | -9.0% | Legislative drug pricing reforms and patent cliffs across blockbuster therapeutics have prompted pharmaceutical sponsors to scrutinize operational overhead. While core regulatory compliance software remains strictly protected, discretionary commercial seat expansion and early-stage biotech module additions face heightened procurement scrutiny, moderating net revenue expansion rates relative to historical pandemic-era highs. |
Veeva Systems: What Could Break or Accelerate the Thesis
Event Risk Score: Low 25/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Systemic clinical GxP compliance compromise | 14% | -34% | A catastrophic cybersecurity breach or systemic data corruption incident within regulatory trial repositories could invalidate pending Phase III trial records under FDA 21 CFR Part 11. Such an audit catastrophe would trigger emergency clinical holds, severe regulatory sanctions, and litigation, permanently impairing the enterprise's trusted reputation and triggering customer churn. |
| Tier-one pharmaceutical migration defection cascade | 22% | -26% | Multiple top-ten pharmaceutical sponsors could revolt against compulsory migration schedules and defect to rival life sciences clouds during renewal windows. A high-profile defection would shatter the market's belief in an unassailable commercial moat, sparking aggressive price discounting across mid-tier accounts and provoking sharp valuation multiple de-rating. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Autonomous clinical trial clearance standardization | 32% | +32% | Global regulatory authorities could formalize direct automated review protocols that accept clinical trial dossiers generated by validated domain AI agents by late 2028. Automating trial document verification would save pharmaceutical sponsors billions, allowing the platform to command lucrative outcome-based licensing that accelerates subscription revenue growth well beyond twenty percent. |
| Full top-twenty commercial platform sweep | 28% | +25% | Operational friction or regulatory compliance failures in competing enterprise clouds could prompt all remaining uncommitted top-twenty pharmaceutical sponsors to standardize exclusively on the proprietary commercial platform ahead of 2029 deadlines. Total commercial consolidation would eliminate platform contestability, unlock multi-year contract expansions, and drive operating margins past thirty-five percent. |
Company Financial AnalysisVeeva Systems: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Veeva Systems financials here.
Earnings and financials
Financial results demonstrate powerful operational momentum driven by non-discretionary software subscriptions. In fiscal 2026, revenue grew 16.3% to $3.20 billion while operating income surged 32.5% to $916 million, supported by the July 2026 quarter delivering $928 million in revenue. Subscription revenues now represent over 80% of sales, providing predictable recurring cash flow across economic cycles. Behind headline expansion, cash flow generation outpaces accounting profits. Trailing twelve-month free cash flow reached $1.64 billion, reflecting an exceptional cash conversion margin above 40%. While implementation services grew quickly to support customer migrations, high-margin subscriptions remain the fundamental engine driving long-term earnings compounding.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | USD 3.2B | USD 908.9M | USD 1.4B |
| 2025 | USD 2.7B | USD 714.1M | USD 1.1B |
| 2024 | USD 2.4B | USD 525.7M | USD 885.1M |
| 2023 | USD 2.2B | USD 487.7M | USD 767M |
| 2022 | USD 1.9B | USD 427.4M | USD 750.2M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2026 | 37.0x | TTM | Native | USD / USD |
| 2025 | 54.9x | TTM | Native | USD / USD |
| 2024 | 65.1x | TTM | Native | USD / USD |
| 2023 | 57.3x | Annual | Native | USD / USD |
| 2022 | 89.8x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profitability margins are expanding structurally as the business achieves software economies of scale. Gross margins reached 75.5% in fiscal 2026, while operating margin expanded to 28.7%, up from 18.2% two years earlier. High pricing power in mission-critical regulatory compliance tools ensures that incremental subscription sales drop directly to operating profit. The critical operational inflection lies in shedding third-party platform licensing fees over the next three years. As customer migrations wrap up, eliminating partner royalties will structurally propel gross margins toward 78%, permanently lifting underlying profitability and protecting cash flows from broader wage inflation.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2026 | USD 916.4M | 28.7% | 28.4% |
| 2025 | USD 691.4M | 25.2% | 26.0% |
| 2024 | USD 429.3M | 18.2% | 22.2% |
| 2023 | USD 459.1M | 21.3% | 22.6% |
| 2022 | USD 505.5M | 27.3% | 23.1% |
Balance sheet and leverage
The balance sheet represents an impregnable financial fortress designed for total strategic independence. At the close of fiscal 2026, total assets reached $8.98 billion against equity of $7.21 billion, backed by zero funded debt and an exceptional current ratio of 4.89. Liquid reserves exceed $6.6 billion in cash and marketable securities. This debt-free structure insulates operations from elevated interest rates and tighter credit markets. Rather than paying interest to lenders, the company earns substantial interest income and deploys surplus capital into a systematic two-billion-dollar share repurchase program, steadily retiring shares without financial risk.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2026 | USD 95.9M | USD 6.6B | USD 1.3B net cash | USD -6.5B | 4.89x |
| 2025 | USD 75.8M | USD 5.2B | USD 1B net cash | USD -5.1B | 4.51x |
| 2024 | USD 55.8M | USD 4B | USD 647.7M net cash | USD -4B | 4.24x |
| 2023 | USD 61M | USD 3.1B | USD 825.5M net cash | USD -3B | 3.94x |
| 2022 | USD 54.6M | USD 2.4B | USD 1.1B net cash | USD -2.3B | 3.70x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The business operates an ultra-capital-light cloud delivery model that requires virtually no physical property investment. Capital expenditures absorbed just 0.91% of revenue in fiscal 2026, totaling under $30 million. By relying on commercial hyperscalers rather than building expensive server farms, management avoids physical inflation and depreciation burdens. Instead, capital reinvestment is directed entirely into intellectual property through expensed research and development, which absorbed $767 million in fiscal 2026. This disciplined allocation self-funds proprietary platform upgrades and specialized AI workflows, generating high returns on invested capital and freeing cash for shareholder returns.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2026 | USD 29.1M | USD 767.4M |
| 2025 | USD 20.5M | USD 693.1M |
| 2024 | USD 26.2M | USD 629M |
| 2023 | USD 13.5M | USD 520.3M |
| 2022 | USD 14.2M | USD 382M |
Behind the synthesisVeeva Systems: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The prevailing reports reveal an independently verifiable common pattern: high customer switching costs anchored in strict regulatory compliance mandates insulate core subscription revenues, while migrating commercial software onto proprietary architecture systematically eliminates third-party platform royalties. However, significant correlated assumptions exist regarding the pace of margin expansion and frictionless account migrations. The strongest contrarian critique correctly demonstrates that a forced migration window temporarily collapses switching costs, inviting aggressive competitive bidding from rival cloud alliances while ongoing dual-platform maintenance and stock-based compensation dilute owner returns. Furthermore, trading at over forty times trailing earnings amidst elevated real discount rates exposes the equity to valuation multiple contraction. Consequently, allocations prioritize empirically verified reports that rigorously account for implementation drag, competitive bidding friction, and cost-of-capital gravity, while downweighting submissions that model uninterrupted multiple expansion and uninhibited pricing power.
All 14 opinions
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 11.2%
Demonstrates outstanding research rigor, cross-referencing Q2 fiscal 2027 transcripts, customer win tallies, and federal policy impacts. It perceptively notes that forced customer migration reopens competitive bidding while simultaneously deepening post-cutover customer lock-in.
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 11.2%
Provides exceptional empirical grounding using primary SEC filings and investor disclosures. It rigorously isolates recurring stock compensation, implementation cost drags, and duration risk at forty-two times trailing earnings, establishing the most disciplined valuation anchor among the submissions.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.4%
Delivers strong empirical grounding with verified primary disclosures on top-twenty biopharma migration commitments. Its balanced view of commercial competitive friction against non-commercial R&D dominance provides high analytical integrity and realistic margin step-up expectations.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.4%
Supplies an indispensable valuation reality check supported by primary data sources. It correctly identifies dual-platform migration overhead, persistent equity compensation claims, and multiple de-rating pressures under elevated sovereign yields, establishing credible boundaries on multiple expansion.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.5%
This analysis presents a balanced appraisal of subscription compounding against professional services margin dilution during migration. The causal linkages between customer lock-in, royalty elimination, and cash conversion are sound, though competitive bidding risks from competing cloud offerings are somewhat minimized.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
The report provides coherent economic reasoning regarding owner earnings and switching costs within regulated life sciences software. However, it relies heavily on frictionless Salesforce migration assumptions and downplays the duration drag of elevated real interest rates on premium valuation multiples.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
The analysis offers thorough evaluation of gross margin expansion unlocked by eliminating third-party hosting royalties. It correctly assesses balance sheet solvency, but its terminal multiple assumptions remain slightly generous relative to sustained five-percent sovereign bond yield benchmarks.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
The thesis correctly identifies regulatory compliance as a powerful institutional barrier against customer churn. However, its rhetorical framing overstates the speed of operating margin harvest while giving limited scrutiny to ongoing equity compensation dilution.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Demonstrates robust reasoning on Development Cloud cross-selling and operating leverage. The forecast trajectory is internally consistent, though it projects aggressive terminal revenue compounding that assumes zero material account losses across mid-tier pharmaceutical renewals.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Offers valuable tactical perspective on enterprise procurement dynamics and regulatory capture. It accurately identifies that customer switching risks protect gross retention, though its terminal multiple projections remain elevated given persistent macroeconomic interest rate tightening.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Effectively separates front-office commercial migration friction from core R&D system-of-record entrenchment. The causal analysis is logical and acknowledges early-stage biotech funding headwinds, though it models rapid AI agent monetization without sufficient regulatory validation discounting.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.6%
Provides a sound macro perspective on credit cycles and non-discretionary pharmaceutical compliance expenditures. However, its earnings growth expectations rely on relatively smooth platform migration execution with minimal allowance for customer pricing concessions.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.7%
Presents an aggressive compounding thesis that overstates near-term pricing dominance. While royalty elimination is an authentic tailwind, projecting doubling equity valuation under restrictive monetary policy underestimates the persistent gravity of enterprise valuation multiple compression.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.7%
Correctly emphasizes capital efficiency and multiple sensitivity, but its excessively punitive terminal multiple assumptions overstate commercial market share erosion and ignore the offsetting resilience of debt-free cash reserves during credit tightening regimes.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Veeva Systems forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web31 available sources from this batch (57 recorded). The first 15 are shown below; expand to read the rest.
- 447148_P45082_Veeva 2026 Proxy_PROOF_REV2_RC_CWO-76010.pdf sec.gov
- 447148_P45082_Veeva 2026 Proxy_PROOF_REV2_RC_CWO-76010.pdf sec.gov
- veev-20260731 sec.gov
- Veeva (VEEV) Q2 2027 Earnings Call Transcript - AOL aol.com
- Veeva Vault CRM vs. Salesforce CRM: Considerations for Migrating or Switching Solutions clarkstonconsulting.com
- VEEV Stock Quote Price and Forecast | CNN cnn.com
- Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox | CSIS csis.org
- Veeva Systems Inc. (VEEV) Stock Price, News, Quote & History - Yahoo Finance finance.yahoo.com
- Veeva (VEEV) Q2 2027 Earnings Call Transcript | The Motley Fool fool.com
- Gloom gloom.sh
- Veeva Vault CRM Migration: A Complete Roadmap & Timeline | IntuitionLabs intuitionlabs.ai
- Veeva Q2’27 slides: revenue beats drive raised guidance, margins hold By Investing.com investing.com
- Veeva Systems A (VEEV) Stock Forecast & Price Target - Investing.com investing.com
- Veeva Systems Inc. - Investor Relations ir.veeva.com
- Veeva Systems Inc. - Veeva Announces Falcon, an Agentic Platform and Standard Agents to Deliver Agentic Labor in Drug Development ir.veeva.com
Show 16 more sources
- Veeva Systems Inc. - Veeva Announces Fiscal 2027 Second Quarter Results ir.veeva.com
- Veeva Systems Inc. - Veeva Announces Fourth Quarter and Fiscal Year 2026 Results ir.veeva.com
- VEEV: Veeva Systems Inc. Stock Price, Chart & Key Stats | LuxAlgo luxalgo.com
- Veeva Systems Q2 2026 Earnings Call Transcript marketbeat.com
- veeva systems lifts outlook crm wins nasdaq.com
- Veeva Systems (VEEV) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 public.com
- Veeva Vault CRM vs Salesforce LSC (2026) | Rx Almanac rxalmanac.com
- August 26, 2026 Q2 FY2027 Earnings Prepared Remarks s206.q4cdn.com
- June 3, 2026 Q1 FY2027 Earnings Prepared Remarks Peter Gassner, Founder & CEO s206.q4cdn.com
- Life Sciences Cloud: June 2026 Newsletter - Salesforce salesforce.com
- Veeva Systems Q1 2025 Earnings Analysis sergeycyw.substack.com
- Most-Favored-Nation Drug Pricing Policy: Executive Actions, Manufacturer Agreements, and Growing Congressional Scrutiny | Insights | Sidley Austin LLP sidley.com
- Veeva Systems (VEEV) Stock Price & Overview stockanalysis.com
- VEEV Stock Forecast 2026 - Veeva Price Targets & Predictions tickernerd.com
- More than 125 Customers Worldwide Live on Vault CRM as Veeva Accelerates the Industry’s Agentic Transformation | Veeva veeva.com
- Veeva Announces Falcon, an Agentic Platform and Standard Agents to Deliver Agentic Labor in Drug Development | Veeva veeva.com
26 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2015-01-31–2026-01-31, 12 periods; Quarterly fiscal periods: 2023-10-31–2026-07-31, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.